Literature DB >> 12810629

An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer.

Lukas A Hefler1, Christoph Grimm, Sven Ackermann, Sabine Malur, Amir R Radjabi-Rahat, Sepp Leodolter, Matthias W Beckmann, Robert Zeillinger, Heinz Koelbl, Clemens B Tempfer.   

Abstract

Interleukin (IL)-6 is known to be involved in the pathogenesis of ovarian cancer. We investigated a common G/C polymorphism at position -174 of the IL-6 gene (IL6) promoter in 121 patients with ovarian cancer using pyrosequencing. Presence of at least one mutant allele was associated with early tumor stage as well as an expanded length of disease-free (DFS) and overall survival with a dose-dependent effect regarding the carriage of 0, 1, and 2 alleles. In a multivariate Cox regression model incorporating tumor stage and residual tumor mass, presence of the -174 C allele of IL6 was the best predictor of DFS. We conclude that the mutant -174 C allele of IL6 influences the biological phenotype of ovarian cancer because it is associated with early stage and improved DFS and overall survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810629

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Interleukin 6 G-174 C polymorphism and breast cancer risk.

Authors:  A M González-Zuloeta Ladd; A Arias Vásquez; J Witteman; A G Uitterlinden; J W Coebergh; A Hofman; B H Ch Stricker; C M van Duijn
Journal:  Eur J Epidemiol       Date:  2006-05-23       Impact factor: 8.082

2.  Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival.

Authors:  Honglin Song; Estrid Hogdall; Susan J Ramus; Richard A Dicioccio; Claus Hogdall; Lydia Quaye; Valerie McGuire; Alice S Whittemore; Mitul Shah; David Greenberg; Douglas F Easton; Susanne Kruger Kjaer; Paul D P Pharoah; Simon A Gayther
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

3.  Association of IL-6 polymorphisms with hepatocellular carcinoma risk: evidences from a meta-analysis.

Authors:  Ying Liu; Su-jun Gao; Bo-xiang Du; Jie-jun Wang
Journal:  Tumour Biol       Date:  2013-12-08

4.  IL-6 polymorphism in non-small cell lung cancer: a prognostic value?

Authors:  Mónica Gomes; Ana Coelho; António Araújo; Andreia Azevedo; Ana Luísa Teixeira; Raquel Catarino; Rui Medeiros
Journal:  Tumour Biol       Date:  2015-01-09

5.  Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma.

Authors:  Ruchi Garg; Melissa Wollan; Vijaya Galic; Rochelle Garcia; Barbara A Goff; Heidi J Gray; Elizabeth Swisher
Journal:  Gynecol Oncol       Date:  2006-10-04       Impact factor: 5.482

6.  Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis.

Authors:  Renata Talar-Wojnarowska; Anita Gasiorowska; Beata Smolarz; Hanna Romanowicz-Makowska; Andrzej Kulig; Ewa Malecka-Panas
Journal:  Dig Dis Sci       Date:  2008-07-26       Impact factor: 3.199

7.  The (-174) G/C polymorphism in the interleukin-6 gene is associated with risk of papillary thyroid carcinoma in Turkish patients.

Authors:  A G Ozgen; M Karadeniz; M Erdogan; A Berdeli; F Saygili; C Yilmaz
Journal:  J Endocrinol Invest       Date:  2009-04-15       Impact factor: 4.256

Review 8.  Serum interleukin-6 levels in colorectal cancer patients--a summary of published results.

Authors:  Heike Knüpfer; Rainer Preiss
Journal:  Int J Colorectal Dis       Date:  2009-11-07       Impact factor: 2.571

9.  Phase II biomarker trial of a multimarker diagnostic for ovarian cancer.

Authors:  Tracey Edgell; G Martin-Roussety; G Barker; D J Autelitano; D Allen; P Grant; G E Rice
Journal:  J Cancer Res Clin Oncol       Date:  2010-01-16       Impact factor: 4.553

10.  TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

Authors:  M Szajnik; M J Szczepanski; M Czystowska; E Elishaev; M Mandapathil; E Nowak-Markwitz; M Spaczynski; T L Whiteside
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.